Targeting a specific protein pathway to improve melanoma treatment

Targeting the SKP2 Axis for Anti-melanoma Therapy

NIH-funded research Beth Israel Deaconess Medical Center · NIH-11123811

This study is looking at a protein called SKP2 to see how it affects melanoma, a serious type of skin cancer, with the goal of finding better treatment options that are more suited to individual patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBeth Israel Deaconess Medical Center NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-11123811 on NIH RePORTER

What this research studies

This research investigates the role of the SKP2 protein in melanoma, a highly aggressive form of skin cancer. By analyzing how SKP2 and other related proteins contribute to the development and progression of melanoma, the research aims to identify new therapeutic targets. The approach includes studying the molecular mechanisms involved in melanoma and exploring how targeting these pathways can enhance treatment effectiveness. Patients may benefit from improved treatment options that are tailored to their specific tumor characteristics.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with melanoma, particularly those with specific genetic alterations in their tumors.

Not a fit: Patients with non-melanoma skin cancers or those whose melanoma has already progressed beyond treatment options may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective therapies for melanoma, potentially improving survival rates and quality of life for patients.

How similar studies have performed: Other research has shown promising results in targeting similar protein pathways in cancer treatment, indicating that this approach may be effective.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.